By Kelly Cloonan
Shares of Neurocrine Biosciences fell after the company's first-quarter revenue beat Wall Street's expectations amid rising sales of its Ingrezza treatment.
The stock rose 12% to $122.92 on Tuesday. Shares have declined 13% over the past 12 months.
The San Diego biopharmaceutical company on Monday evening posted a profit of $7.9 million, or 8 cents a share, compared with $43.4 million, or 42 cents a share, a year earlier.
Adjusted earnings per share were 70 cents, below estimates of $1.18 a share according to analysts polled by FactSet.
Revenue rose to $572.6 million compared with $515.3 million a year earlier. Analysts expected $559.6 million.
Sales of Ingrezza, the company's treatment for tardive dyskinesia and chorea associated with Huntington's disease, rose 8% from the prior year to $545.2 million.
"We delivered a record number of new patient starts for Ingrezza, which is especially impressive given the typically challenging first quarter," Chief Executive Kyle Gano said.
For the full year, the company reaffirmed its previous outlook, guiding for Ingrezza sales of $2.5 billion to $2.6 billion.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
May 06, 2025 11:00 ET (15:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。